Diabetes News and Research

Latest Diabetes News and Research

Blocking a key protein protects against metabolic liver damage

Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some fraction of those livers develop scarring, become inflamed, and eventually fail. University of Utah researchers have identified a protein, EFHD1, that appears to drive that transition by triggering an out-of-place antiviral immune response.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

CAC-based statin initiation shows no difference in major cardiovascular events

There was no difference in major cardiovascular events when statin initiation was based on coronary artery calcium compared with traditional risk factor assessment, according to results presented in a Hot Line session today at ESC Congress 2026.

31 Aug 2026

Routine referral of prostate cancer patients to a cardiovascular specialist fails to cut cardiac events

Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Starting statins early after diabetes diagnosis linked to lower dementia risk

Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

People with diabetes may have another reason to protect their cardiovascular health

Better cardiovascular health, measured using Life’s Essential 8, was associated with a lower risk of mild cognitive impairment among people with diabetes after accounting for genetic susceptibility. Associations with dementia varied by genetic risk, while higher LE8 scores were also linked to greater gray matter volume and lower white matter hyperintensity volume.

30 Aug 2026

Your skin may offer clues about how many fruits and vegetables you eat

In an exploratory study of 137 Australian adults, skin yellowness measured by reflectance spectroscopy was associated with combined fruit and vegetable intake, fruit intake alone, total carotenoid intake, body fat percentage and skin color. The findings suggest skin measurements could provide an objective dietary biomarker, but the researchers caution that skin color, ethnicity and other individual characteristics may influence how the measurements are interpreted.

30 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Type 1 diabetes cases projected to increase worldwide by 2049

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049.

28 Aug 2026

Study identifies role for peroxisomes in protecting insulin and maintaining beta cell health

Researchers at LSU's Pennington Biomedical Research Center have identified a previously underappreciated role for tiny structures inside cells called peroxisomes in protecting insulin and maintaining the health and maturity of insulin-producing pancreatic beta cells.

28 Aug 2026

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

In a large Australian cohort of adults with hypertension, use of blood-brain barrier-crossing antihypertensive medications was associated with a lower risk of dementia and mortality than use of non-crossing drugs. The association was strongest for beta-blockers and angiotensin II receptor blockers, although the observational design means the findings cannot establish causality.

27 Aug 2026

Scientists reviewed 20 edible and medicinal fungi for clues to better prebiotics

A review of 20 non-toxic edible and medicinal fungal species found that their polysaccharides can resist digestion, interact with gut microbes, and influence microbial metabolites linked to intestinal and metabolic health. The evidence suggests potential benefits for conditions including colitis, type 2 diabetes, and obesity, although most findings currently come from laboratory and animal studies.

27 Aug 2026

Diabetes News and Research

Latest Diabetes News and Research

Blocking a key protein protects against metabolic liver damage

Study identifies three distinct BMI trajectories among people with type 2 diabetes

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

Semaglutide did more than cut weight in this analysis of 6,239 adults

CAC-based statin initiation shows no difference in major cardiovascular events

Routine referral of prostate cancer patients to a cardiovascular specialist fails to cut cardiac events

Experts call for safer weight loss as concerns grow over GLP-1 use

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

Starting statins early after diabetes diagnosis linked to lower dementia risk

Met-HeFT trial finds no cardiovascular benefit from metformin

H-ISDN shows no significant benefit in broader heart failure population

People with diabetes may have another reason to protect their cardiovascular health

Your skin may offer clues about how many fruits and vegetables you eat

Trial shows antiplatelet therapy needs personalization after stent implantation

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

Type 1 diabetes cases projected to increase worldwide by 2049

Study identifies role for peroxisomes in protecting insulin and maintaining beta cell health

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

Scientists reviewed 20 edible and medicinal fungi for clues to better prebiotics

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Diabetes News and Research

Latest Diabetes News and Research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Newsletters you may be interested in